Dompé Pharmaceuticals has announced the sale of six brands to French Substipharm, which specializes in niche generic and pharmaceutical products. The brands involved in the agreement are: Eparmefolin (antiemetic), Citofolin (calcium folinate supplement), Luminale (general sedative), Memac (acetylcholinesterase inhibitor), Rigentex (vitamin E), Broncomnes (mucus regulator).

"Our objective is to strengthen our commitment to strategic areas and brands for Italy and continue the geographical expansion project for Primary Care," says Davide Polimeni, Chief Commercial Officer Primary Care of Dompé Pharmaceuticals. "This operation on the Italian market is part of a focused path that will see us increasingly committed to enhancing corporate assets in a critical investment and development program for our key brands, in line with our five years strategic plan."

“This deal is a key milestone for us in our international development strategy. That includes working hard with the best partners both at home and internationally, and Dompé’s similar values and strong reputation in Italy makes them a perfect fit” – Philippe Beaupere. Operations Commercial Director – Mergers & Acquisitions, Substipharm. “We are very much looking forward to working with the Dompé teams, ensuring a smooth transition for every patient in Italy.”

Dompé achieved in 2020 a turnover of approximately € 550 million, with a 15% investment in R&D and 60 million products commercialized. The two key business areas are Primary Care and Biotech. Primary Care includes a broad spectrum of therapeutic solutions and brands leaders in important market segments such as pain, respiratory, cardiometabolic and prevention. Biotech focuses on the development of treatments for rare diseases with high social impact. The main therapeutic areas include pain relief, inflammation, ophthalmology, diabetes care, nutrition and oncology.